Drugs / DWC202511
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07213310 | Nov 2025 → Jan 2026 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DWC202511 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07213310 ↗ |
| Route | Oral | “Repeated oral administration of DWC202511 500 mg twice daily (BID), in accordance with the study protocol.” NCT07213310 ↗ |